A Phase 2/3 interventional study of Placebo and Adalimumab 80 mg in Rheumatoid Arthritis, sponsored by Abbott. Completed at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-11.
Sponsored by Abbott · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 31st largest by enrollment, is one of 7 that started in 2007, is one of 3 in phase 2/3, and was the 20th registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 302 is above the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
33 studies in Arthritis, Rheumatoid by Abbott: none open now, none under way, none of them phase 3. Of 30 finished, 19 (63%) have results posted.
Among the 33 studies in Arthritis, Rheumatoid by Abbott, this one is the 12th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2007, is one of 2 in phase 2/3, and was the 15th registered.
Abbott’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 33 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to assess the safety and efficacy of adalimumab administered as a subcutaneous injection in adult Chinese subjects with rheumatoid arthritis and treated with methotrexate
This was a multi-center, Phase 2/3, randomized, double-blind (DB), parallel group, placebo controlled, safety and efficacy study in adult Chinese RA subjects. The duration of the study was approximately 116 weeks. This included a 4-week (28 days) Screening period, a 12-week Double-Blind (DB) period, a 90-week Open-Label (OL) Period, and a 10-week (70 days) Follow-up period. The 70-day Safety Follow-up period was initiated after the last dose of study medication.
During the DB period, 302 Chinese subjects with RA and concomitantly treated with MTX were enrolled at 11 clinical sites located throughout China. Subjects were randomly assigned to one of the three treatment groups in a 2:2:1 ratio: 80 mg adalimumab, 40 mg adalimumab, or placebo. From Week 0 to Week 10, subjects received blinded study drug. Subjects who successfully participated and completed Week 12 of the DB portion of the study participated in the OL period. All subjects in the OL period received adalimumab 40 mg. Throughout the study, the study drug was administered subcutaneously (SC) every other week (eow).
Subjects that completed the Week 24 visit, prior to the approval of Protocol Amendment 1, had 70 days from the last dose of study drug to re-enter the study. The Investigator confirmed that the subject did not develop any of the exclusion criteria and completed the procedures defined by the OL Screening visit.
Results through Week 24 of this study were presented in the regulatory dossier for the marketing authorization application of Humira in China, fulfilling the requirement for clinical data in Chinese patients. However, in order to continue to provide treatment to patients who responded well to adalimumab, subjects had the option to continue in the OL extension of this study until Week 92.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo administered subcutaneously every other week
Biological: Placebo
Adalimumab 80 mg administered subcutaneously every other week
Biological: Adalimumab 80 mg
Adalimumab 40 mg administered subcutaneously every other week
Biological: Adalimumab 40 mg
Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
Also known as: Humira
Adalimumab 40 mg administered subcutaneously every other week for 104 weeks
Also known as: Humira
Number of Participants With American College of Rheumatology (ACR)20 at Week 12 of the Double-Blind Period
American College of Rheumatology (ACR) criteria improvement consisting of 20% (ACR20) reduction in tender or swollen joint counts and 20% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit. Week 12 = end of Double-Blind period.
Time frame: Week 12
Number of Participants Achieving American College of Rheumatology (ACR)50/70 at Week 12 of the Double-Blind Period
American College of Rheumatology (ACR) criteria improvement consisting of 50% or 70% (ACR50/70) reduction in tender or swollen joint counts and 50% or 70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit. Week 12 = end of Double-blind period.
Time frame: Week 12
Number of Participants Achieving American College of Rheumatology (ACR)20 Response Through Week 92 of Open-Label Period
American College of Rheumatology (ACR) criteria improvement in a subject's disease condition versus Baseline consisting of 20% (ACR20) reduction in tender or swollen joint counts and 20/50/70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.
Time frame: Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Number of Participants Achieving American College of Rheumatology (ACR)50 Response Through Week 92 of Open-Label Period
American College of Rheumatology (ACR) criteria improvement in a subject's disease condition versus Baseline consisting of 50% (ACR50) reduction in tender or swollen joint counts and 20/50/70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.
Time frame: Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Number of Participants Achieving American College of Rheumatology (ACR)70 Response Through Week 92 of Open-Label Period
American College of Rheumatology (ACR) criteria improvement in a subject's disease condition versus Baseline consisting of 70% (ACR70) reduction in tender or swollen joint counts and 20/50/70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.
Time frame: Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Mean Change in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 12 of the Double-Blind Period
Sixty-eight or 66 joints or regions (34 or 32 per body side \[hip joints excluded\]) were assessed by pressure and joint manipulation on physical examination for tender joint count (TJC) or swollen joint count (SJC), respectively. Both joint tenderness and swelling were classified as either present ("1"), absent ("0"), replaced ("9"), or no assessment ("NA"). The Total TJC or SJC was derived as the sum of all 1s evaluated; the range for TJC and SJC were 0 - 68 and 0 - 66, respectively. The higher the joint count, the worse the rheumatoid arthritis. Week 12 = end of Double-Blind period.
Time frame: Baseline, Week 12
Mean Change in Tender Joint Count (TJC) Through Week 92 of the Open-Label Period
Sixty-eight or 66 joints or regions (34 or 32 per body side \[hip joints excluded\]) were assessed by pressure and joint manipulation on physical examination for tender joint count (TJC) or swollen joint count (SJC), respectively. Both joint tenderness and swelling were classified as either present ("1"), absent ("0"), replaced ("9"), or no assessment ("NA"). The Total TJC or SJC was derived as the sum of all 1s evaluated; the range for TJC and SJC were 0 - 68 and 0 - 66, respectively. The higher the joint count, the worse the rheumatoid arthritis. Week 12 = end of Double-Blind period.
Time frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Mean Change in Swollen Joint Count (SJC) Through Week 92 of the Open-Label Period
Sixty-eight or 66 joints or regions (34 or 32 per body side \[hip joints excluded\]) were assessed by pressure and joint manipulation on physical examination for tender joint count (TJC) or swollen joint count (SJC), respectively. Both joint tenderness and swelling were classified as either present ("1"), absent ("0"), replaced ("9"), or no assessment ("NA"). The Total TJC or SJC was derived as the sum of all 1s evaluated; the range for TJC and SJC were 0 - 68 and 0 - 66, respectively. The higher the joint count, the worse the rheumatoid arthritis. Week 12 = end of Double-Blind period.
Time frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Mean Change in Visual Analog Scale (VAS) Score at Week 12 of the Double-Blind Period
Visual analog scale (VAS) was used for the physician's (PhGA) and patient's (PGA) global assessment of disease activity and the patient's assessment of pain. PhGA assessed the patient's current status, PGA assessed status within the last 24 h, and patient's assessment of pain assessed pain status during the last week. All 3 assessments were scored on a 100 mm horizontal scale. The scores range from 0 (no symptoms) to 100 (maximum symptoms); therefore lower VAS scores represent a better disease state. Week 12 = end of Double-Blind period.
Time frame: Baseline, Week 12
Mean Change in Physician's Global Assessment of Disease Activity (Visual Analog Scale [VAS]) Through Week 92 of the Open-Label Period
Visual analog scale (VAS) was used for the physician's (PhGA) and patient's (PGA) global assessment of disease activity and the patient's assessment of pain. PhGA assessed the patient's current status, PGA assessed status within the last 24 h, and patient's assessment of pain assessed pain status during the last week. All 3 assessments were scored on a 100 mm horizontal scale. The scores range from 0 (no symptoms) to 100 (maximum symptoms); therefore lower VAS scores represent a better disease state.
Time frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Mean Change in Patient's Assessment of Pain (Visual Analog Scale [VAS]) Through Week 92 of the Open-Label Period
Visual analog scale (VAS) was used for the physician's (PhGA) and patient's (PGA) global assessment of disease activity and the patient's assessment of pain. PhGA assessed the patient's current status, PGA assessed status within the last 24 h, and patient's assessment of pain assessed pain status during the last week. All 3 assessments were scored on a 100 mm horizontal scale. The scores range from 0 (no symptoms) to 100 (maximum symptoms); therefore lower VAS scores represent a better disease state.
Time frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Mean Change in Patient's Global Assessment of Disease Activity (Visual Analog Scale [VAS]) Through Week 92 of the Open-Label Period
Visual analog scale (VAS) was used for the physician's (PhGA) and patient's (PGA) global assessment of disease activity and the patient's assessment of pain. PhGA assessed the patient's current status, PGA assessed status within the last 24 h, and patient's assessment of pain assessed pain status during the last week. All 3 assessments were scored on a 100 mm horizontal scale. The scores range from 0 (no symptoms) to 100 (maximum symptoms); therefore lower VAS scores represent a better disease state.
Time frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Mean Change in the Disability Index of the Health Assessment Questionnaire (HAQ) Scores From Baseline to Week 12 of the Double-Blind Period
HAQ is a self-reported, subject-oriented outcome measure. The Standard Disability Index of HAQ for a subject is calculated as the mean of the following 8 category scores (range: 0-3): dressing and grooming, rising, eating, walking, hygiene, reach, grip, and activities. The score of each category is calculated as the maximum of the scores for the questions of that category. The Disability Index cannot be computed if the patient does not have scores for at least 6 categories. A decrease in the Disability Index = improvement in disease (0 = no difficulties). Week 12 = end of Double-Blind period.
Time frame: Baseline, Week 12
Mean Change in the Disability Index of the Health Assessment Questionnaire (HAQ) Through Week 92 of the Open-Label Period
HAQ is a self-reported, subject-oriented outcome measure. The Standard Disability Index of HAQ for a subject is calculated as the mean of the following 8 category scores (range: 0-3): dressing and grooming, rising, eating, walking, hygiene, reach, grip, and activities. The score of each category is calculated as the maximum of the scores for the questions of that category. The Disability Index cannot be computed if the patient does not have scores for at least 6 categories. A decrease in the Disability Index indicates an improvement in disease (0 = no difficulties).
Time frame: Baseline, Week 0, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Mean Change in the SF-36 Health Survey Index Physical Component Summary (PCS) and Mental Component Summary (MCS) at Week 12 of the Double-Blind Period
SF-36 (v.2) is a standardized health survey consisting of 36 questions to measure functional health status. The SF-36 score has two components: physical (PCS) and mental (MCS). Summary scores are calculated using the following 8 scales: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The score for a component is an average of the individual question scores, which are scaled 0 (not functioning) to 100 (highest functioning). An increase in SF-36 PCS or MCS indicates improved health status.
Time frame: Baseline, Week 12
Mean Change in the SF-36 Health Survey Index Physical Component Summary (PCS) Through Week 92 of the Open-Label Period
SF-36 (v.2) is a standardized health survey consisting of 36 questions to measure functional health status. The SF-36 score has two components: physical (PCS) and mental (MCS). Summary scores are calculated using the following 8 scales: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The score for a component is an average of the individual question scores, which are scaled 0 (not functioning) to 100 (highest functioning). An increase in SF-36 PCS or MCS indicates improved health status.
Time frame: Baseline, Week 0, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
Mean Change in the SF-36 Health Survey Index Mental Component Summary (MCS) Through Week 92 of the Open-Label Period
SF-36 (v.2) is a standardized health survey consisting of 36 questions to measure functional health status. The SF-36 score has two components: physical (PCS) and mental (MCS). Summary scores are calculated using the following 8 scales: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The score for a component is an average of the individual question scores, which are scaled 0 (not functioning) to 100 (highest functioning). An increase in SF-36 PCS or MCS indicates improved health status.
Time frame: Baseline, Week 0, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84, Week 92
| Milestone | Placebo | Adalimumab 40 mg | Adalimumab 80 mg |
|---|---|---|---|
| Started | 60 | 121 | 121 |
| Completed | 59 | 119 | 116 |
| Not completed | 1 | 2 | 5 |
| Withdrew: Adverse event | 1 | 2 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Various | 0 | 0 | 0 |
| Milestone | Placebo | Adalimumab 40 mg | Adalimumab 80 mg |
|---|---|---|---|
| Started | 59 | 119 | 116 |
| Completed | 23 | 55 | 52 |
| Not completed | 36 | 64 | 64 |
| Withdrew: Adverse event | 2 | 10 | 11 |
| Withdrew: Withdrawal by subject | 15 | 19 | 25 |
| Withdrew: Lost to follow-up | 1 | 10 | 6 |
| Withdrew: Various | 18 | 25 | 22 |
American College of Rheumatology (ACR) criteria improvement consisting of 20% (ACR20) reduction in tender or swollen joint counts and 20% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit. Week 12 = end of Double-Blind period.
| Participants | Placebo | Adalimumab 40 mg | Adalimumab 80 mg |
|---|---|---|---|
| Number of Participants With American College of Rheumatology (ACR)20 at Week 12 of the Double-Blind Period | 21 | 69 | 62 |
American College of Rheumatology (ACR) criteria improvement consisting of 50% or 70% (ACR50/70) reduction in tender or swollen joint counts and 50% or 70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit. Week 12 = end of Double-blind period.
| Participants | Placebo | Adalimumab 40 mg | Adalimumab 80 mg |
|---|---|---|---|
| ACR50 | 9 | 39 | 29 |
| ACR70 | 2 | 19 | 11 |
American College of Rheumatology (ACR) criteria improvement in a subject's disease condition versus Baseline consisting of 20% (ACR20) reduction in tender or swollen joint counts and 20/50/70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.
| Participants | All Open-Label Adalimumab |
|---|---|
| Week 0 Responders (n = 293) | 152 |
| Week 4 Responders (n = 289) | 179 |
| Week 8 Responders (n = 283) | 183 |
| Week 12 Responders (n = 279) | 207 |
| Week 24 Responders (n = 208) | 153 |
| Week 36 Responders (n = 200) | 158 |
| Week 48 Responders (n = 183) | 147 |
| Week 60 Responders (n = 166) | 131 |
| Week 72 Responders (n = 150) | 108 |
| Week 84 Responders (n = 137) | 111 |
| Week 92 Responders (n = 130) | 105 |
American College of Rheumatology (ACR) criteria improvement in a subject's disease condition versus Baseline consisting of 50% (ACR50) reduction in tender or swollen joint counts and 20/50/70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.
| Participants | All Open-Label Adalimumab |
|---|---|
| Week 0 Responders (n = 293) | 77 |
| Week 4 Responders (n = 289) | 95 |
| Week 8 Responders (n = 283) | 103 |
| Week 12 Responders (n = 279) | 119 |
| Week 24 Responders (n = 208) | 96 |
| Week 36 Responders (n = 200) | 102 |
| Week 48 Responders (n = 183) | 94 |
| Week 60 Responders (n = 166) | 74 |
| Week 72 Responders (n = 150) | 79 |
| Week 84 Responders (n = 137) | 74 |
| Week 92 Responders (n = 130) | 69 |
American College of Rheumatology (ACR) criteria improvement in a subject's disease condition versus Baseline consisting of 70% (ACR70) reduction in tender or swollen joint counts and 20/50/70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.
| Participants | All Open-Label Adalimumab |
|---|---|
| Week 0 Responders (n = 293) | 32 |
| Week 4 Responders (n = 289) | 39 |
| Week 8 Responders (n = 283) | 49 |
| Week 12 Responders (n = 279) | 52 |
| Week 24 Responders (n = 208) | 39 |
| Week 36 Responders (n = 200) | 48 |
| Week 48 Responders (n = 183) | 40 |
| Week 60 Responders (n = 166) | 37 |
| Week 72 Responders (n = 150) | 30 |
| Week 84 Responders (n = 137) | 38 |
| Week 92 Responders (n = 130) | 34 |
Sixty-eight or 66 joints or regions (34 or 32 per body side \[hip joints excluded\]) were assessed by pressure and joint manipulation on physical examination for tender joint count (TJC) or swollen joint count (SJC), respectively. Both joint tenderness and swelling were classified as either present ("1"), absent ("0"), replaced ("9"), or no assessment ("NA"). The Total TJC or SJC was derived as the sum of all 1s evaluated; the range for TJC and SJC were 0 - 68 and 0 - 66, respectively. The higher the joint count, the worse the rheumatoid arthritis. Week 12 = end of Double-Blind period.
| Joints | Placebo | Adalimumab 40 mg | Adalimumab 80 mg |
|---|---|---|---|
| TJC Week 12 | -7.0 ± 12.1 | -12.2 ± 14.9 | -8.8 ± 12.6 |
| SJC Week 12 | -4.7 ± 8.7 | -8.6 ± 8.6 | -6.4 ± 6.6 |
Sixty-eight or 66 joints or regions (34 or 32 per body side \[hip joints excluded\]) were assessed by pressure and joint manipulation on physical examination for tender joint count (TJC) or swollen joint count (SJC), respectively. Both joint tenderness and swelling were classified as either present ("1"), absent ("0"), replaced ("9"), or no assessment ("NA"). The Total TJC or SJC was derived as the sum of all 1s evaluated; the range for TJC and SJC were 0 - 68 and 0 - 66, respectively. The higher the joint count, the worse the rheumatoid arthritis. Week 12 = end of Double-Blind period.
| Joints | All Open-Label Adalimumab |
|---|---|
| Baseline | 22.8 ± 16.07 |
| Week 0 (n = 293) | -9.9 ± 13.44 |
| Week 4 (n = 289) | -12.3 ± 13.08 |
| Week 8 (n = 283) | -13.4 ± 13.68 |
| Week 12 (n = 279) | -14.4 ± 14.15 |
| Week 24 (n = 208) | -16.4 ± 13.54 |
| Week 36 (n = 200) | -16.5 ± 13.57 |
| Week 48 (n = 183) | -17.6 ± 14.24 |
| Week 60 (n = 166) | -17.0 ± 13.99 |
| Week 72 (n = 150) | -18.0 ± 14.15 |
| Week 84 (n = 137) | -18.5 ± 15.18 |
| Week 92 (n = 130) | -18.0 ± 14.23 |
Sixty-eight or 66 joints or regions (34 or 32 per body side \[hip joints excluded\]) were assessed by pressure and joint manipulation on physical examination for tender joint count (TJC) or swollen joint count (SJC), respectively. Both joint tenderness and swelling were classified as either present ("1"), absent ("0"), replaced ("9"), or no assessment ("NA"). The Total TJC or SJC was derived as the sum of all 1s evaluated; the range for TJC and SJC were 0 - 68 and 0 - 66, respectively. The higher the joint count, the worse the rheumatoid arthritis. Week 12 = end of Double-Blind period.
| Joints | All Open-Label Adalimumab |
|---|---|
| Baseline | 11.2 ± 7.74 |
| Week 0 (n = 293) | -6.9 ± 8.03 |
| Week 4 (n = 289) | -7.4 ± 8.87 |
| Week 8 (n = 283) | -8.3 ± 8.16 |
| Week 12 (n = 279) | -8.8 ± 7.87 |
| Week 24 (n = 208) | -9.3 ± 8.62 |
| Week 36 (n = 200) | -9.3 ± 8.41 |
| Week 48 (n = 183) | -9.7 ± 8.45 |
| Week 60 (n = 166) | -9.0 ± 7.95 |
| Week 72 (n = 150) | -9.2 ± 7.90 |
| Week 84 (n = 137) | -9.5 ± 7.99 |
| Week 92 (n = 130) | -9.5 ± 8.00 |
Visual analog scale (VAS) was used for the physician's (PhGA) and patient's (PGA) global assessment of disease activity and the patient's assessment of pain. PhGA assessed the patient's current status, PGA assessed status within the last 24 h, and patient's assessment of pain assessed pain status during the last week. All 3 assessments were scored on a 100 mm horizontal scale. The scores range from 0 (no symptoms) to 100 (maximum symptoms); therefore lower VAS scores represent a better disease state. Week 12 = end of Double-Blind period.
| mm | Placebo | Adalimumab 40 mg | Adalimumab 80 mg |
|---|---|---|---|
| PhGA, Week 12 | -20.6 ± 19.1 | -25.1 ± 22.7 | -20.9 ± 19.7 |
| Pain, Week 12 | -14.9 ± 26 | -22.7 ± 25.2 | -16.4 ± 22.4 |
| PGA, Week 12 | -13.8 ± 26.2 | -23.6 ± 25.2 | -16.3 ± 25.5 |
Visual analog scale (VAS) was used for the physician's (PhGA) and patient's (PGA) global assessment of disease activity and the patient's assessment of pain. PhGA assessed the patient's current status, PGA assessed status within the last 24 h, and patient's assessment of pain assessed pain status during the last week. All 3 assessments were scored on a 100 mm horizontal scale. The scores range from 0 (no symptoms) to 100 (maximum symptoms); therefore lower VAS scores represent a better disease state.
| mm | All Open-Label Adalimumab |
|---|---|
| Baseline | 60.1 ± 16.40 |
| Week 0 (n = 293) | -22.8 ± 20.67 |
| Week 4 (n = 289) | -25.5 ± 21.27 |
| Week 8 (n = 283) | -28.3 ± 22.17 |
| Week 12 (n = 279) | -31.3 ± 21.15 |
| Week 24 (n = 208) | -30.7 ± 20.88 |
| Week 36 (n = 200) | -33.6 ± 21.03 |
| Week 48 (n = 183) | -33.5 ± 20.58 |
| Week 60 (n = 166) | -32.6 ± 21.86 |
| Week 72 (n = 150) | -32.6 ± 22.26 |
| Week 84 (n = 137) | -33.8 ± 20.99 |
| Week 92 (n = 130) | -35.0 ± 19.02 |
Visual analog scale (VAS) was used for the physician's (PhGA) and patient's (PGA) global assessment of disease activity and the patient's assessment of pain. PhGA assessed the patient's current status, PGA assessed status within the last 24 h, and patient's assessment of pain assessed pain status during the last week. All 3 assessments were scored on a 100 mm horizontal scale. The scores range from 0 (no symptoms) to 100 (maximum symptoms); therefore lower VAS scores represent a better disease state.
| mm | All Open-Label Adalimumab |
|---|---|
| Baseline | 60.5 ± 19.19 |
| Week 0 (n = 293) | -18.7 ± 23.96 |
| Week 4 (n = 289) | -21.1 ± 24.55 |
| Week 8 (n = 283) | -23.3 ± 26.25 |
| Week 12 (n = 279) | -27.1 ± 24.34 |
| Week 24 (n = 208) | -25.4 ± 23.46 |
| Week 36 (n = 200) | -27.4 ± 24.86 |
| Week 48 (n = 183) | -27.0 ± 25.81 |
| Week 60 (n = 166) | -28.0 ± 26.54 |
| Week 72 (n = 150) | -26.4 ± 28.14 |
| Week 84 (n = 137) | -27.8 ± 24.71 |
| Week 92 (n = 130) | -27.1 ± 25.41 |
Visual analog scale (VAS) was used for the physician's (PhGA) and patient's (PGA) global assessment of disease activity and the patient's assessment of pain. PhGA assessed the patient's current status, PGA assessed status within the last 24 h, and patient's assessment of pain assessed pain status during the last week. All 3 assessments were scored on a 100 mm horizontal scale. The scores range from 0 (no symptoms) to 100 (maximum symptoms); therefore lower VAS scores represent a better disease state.
| mm | All Open-Label Adalimumab |
|---|---|
| Baseline | 60.7 ± 19.61 |
| Week 0 (n = 293) | -19.0 ± 25.18 |
| Week 4 (n = 289) | -21.0 ± 26.19 |
| Week 8 (n = 283) | -23.6 ± 26.88 |
| Week 12 (n = 279) | -26.3 ± 25.79 |
| Week 24 (n = 208) | -26.6 ± 25.13 |
| Week 36 (n = 200) | -29.8 ± 25.32 |
| Week 48 (n = 183) | -30.5 ± 26.02 |
| Week 60 (n = 166) | -28.7 ± 28.38 |
| Week 72 (n = 150) | -28.7 ± 25.98 |
| Week 84 (n = 137) | -30.5 ± 25.62 |
| Week 92 (n = 130) | -29.6 ± 25.04 |
HAQ is a self-reported, subject-oriented outcome measure. The Standard Disability Index of HAQ for a subject is calculated as the mean of the following 8 category scores (range: 0-3): dressing and grooming, rising, eating, walking, hygiene, reach, grip, and activities. The score of each category is calculated as the maximum of the scores for the questions of that category. The Disability Index cannot be computed if the patient does not have scores for at least 6 categories. A decrease in the Disability Index = improvement in disease (0 = no difficulties). Week 12 = end of Double-Blind period.
| score on a scale | Placebo | Adalimumab 40 mg | Adalimumab 80 mg |
|---|---|---|---|
| Mean Change in the Disability Index of the Health Assessment Questionnaire (HAQ) Scores From Baseline to Week 12 of the Double-Blind Period | -0.3 ± 0.7 | -0.5 ± 0.5 | -0.4 ± 0.6 |
HAQ is a self-reported, subject-oriented outcome measure. The Standard Disability Index of HAQ for a subject is calculated as the mean of the following 8 category scores (range: 0-3): dressing and grooming, rising, eating, walking, hygiene, reach, grip, and activities. The score of each category is calculated as the maximum of the scores for the questions of that category. The Disability Index cannot be computed if the patient does not have scores for at least 6 categories. A decrease in the Disability Index indicates an improvement in disease (0 = no difficulties).
| score on a scale | All Open-Label Adalimumab |
|---|---|
| Baseline | 1.38 ± 0.692 |
| Week 0 (n = 293) | -0.42 ± 0.575 |
| Week 4 (n = 289) | -0.51 ± 0.584 |
| Week 8 (n = 283) | -0.55 ± 0.621 |
| Week 12 (n = 279) | -0.61 ± 0.620 |
| Week 24 (n = 208) | -0.56 ± 0.617 |
| Week 36 (n = 200) | -0.58 ± 0.609 |
| Week 48 (n = 183) | -0.60 ± 0.622 |
| Week 60 (n = 166) | -0.65 ± 0.631 |
| Week 72 (n = 150) | -0.65 ± 0.603 |
| Week 84 (n = 137) | -0.63 ± 0.590 |
| Week 92 (n = 130) | -0.62 ± 0.591 |
SF-36 (v.2) is a standardized health survey consisting of 36 questions to measure functional health status. The SF-36 score has two components: physical (PCS) and mental (MCS). Summary scores are calculated using the following 8 scales: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The score for a component is an average of the individual question scores, which are scaled 0 (not functioning) to 100 (highest functioning). An increase in SF-36 PCS or MCS indicates improved health status.
| score on a scale | Placebo | Adalimumab 40 mg | Adalimumab 80 mg |
|---|---|---|---|
| Physical Component Score, Week 12 | 4.2 ± 7.1 | 5.7 ± 7.3 | 4.5 ± 7.6 |
| Mental Component Score, Week 12 | 3.5 ± 11.8 | 4.9 ± 10.7 | 2.5 ± 12.1 |
SF-36 (v.2) is a standardized health survey consisting of 36 questions to measure functional health status. The SF-36 score has two components: physical (PCS) and mental (MCS). Summary scores are calculated using the following 8 scales: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The score for a component is an average of the individual question scores, which are scaled 0 (not functioning) to 100 (highest functioning). An increase in SF-36 PCS or MCS indicates improved health status.
| score on a scale | All Open-Label Adalimumab |
|---|---|
| Baseline | 32.14 ± 7.759 |
| Week 0 (n = 293) | 5.01 ± 7.356 |
| Week 12 (n = 283) | 7.15 ± 8.225 |
| Week 24 (n = 208) | 6.8 ± 7.251 |
| Week 36 (n = 200) | 7.96 ± 7.478 |
| Week 48 (n = 183) | 8.17 ± 8.046 |
| Week 60 (n = 166) | 8.29 ± 7.666 |
| Week 72 (n = 150) | 7.77 ± 8.806 |
| Week 84 (n = 137) | 8.38 ± 8.182 |
| Week 92 (n = 130) | 8.49 ± 8.195 |
SF-36 (v.2) is a standardized health survey consisting of 36 questions to measure functional health status. The SF-36 score has two components: physical (PCS) and mental (MCS). Summary scores are calculated using the following 8 scales: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The score for a component is an average of the individual question scores, which are scaled 0 (not functioning) to 100 (highest functioning). An increase in SF-36 PCS or MCS indicates improved health status.
| score on a scale | All Open-Label Adalimumab |
|---|---|
| Baseline | 36.50 ± 10.894 |
| Week 0 (n = 293) | 3.74 ± 11.494 |
| Week 12 (n = 283) | 5.73 ± 12.686 |
| Week 24 (n = 208) | 5.22 ± 11.699 |
| Week 36 (n = 200) | 5.51 ± 11.268 |
| Week 48 (n = 183) | 5.29 ± 11.285 |
| Week 60 (n = 166) | 5.56 ± 10.716 |
| Week 72 (n = 150) | 4.75 ± 10.825 |
| Week 84 (n = 137) | 5.09 ± 11.998 |
| Week 92 (n = 130) | 4.14 ± 11.867 |
Collected over The duration for adverse event reporting was 92 weeks. Data from the Double-Blind period (Week 0 through Week 12) and from any adalimumab exposure (Week 0 through Week 92) were reported.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB Phase - Placebo EOW | — | 0/60 (0%) | 11/60 (18.3%) |
| DB Phase - Adalimumab 40 mg EOW | — | 0/121 (0%) | 30/121 (24.8%) |
| DB Phase - Adalimumab 80 mg EOW | — | 3/121 (2.5%) | 27/121 (22.3%) |
| Any Adalimumab | — | 23/301 (7.6%) | 84/301 (27.9%) |
| Event | DB Phase - Placebo EOW | DB Phase - Adalimumab 40 mg EOW | DB Phase - Adalimumab 80 mg EOW | Any Adalimumab |
|---|---|---|---|---|
| Pulmonary tuberculosisInfections and infestations | 0/60 | 0/121 | 0/121 | 5/301 |
| Cerebral hemorrhageNervous system disorders | 0/60 | 0/121 | 1/121 | 1/301 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/60 | 0/121 | 1/121 | 1/301 |
| Hypertensive crisisVascular disorders | 0/60 | 0/121 | 1/121 | 1/301 |
| Lymph node painBlood and lymphatic system disorders | 0/60 | 0/121 | 1/121 | 1/301 |
| LymphadenopathyBlood and lymphatic system disorders | 0/60 | 0/121 | 1/121 | 1/301 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 0/60 | 0/121 | 1/121 | 0/301 |
| Acute myocardial infarctionCardiac disorders | 0/60 | 0/121 | 0/121 | 2/301 |
| Disseminated tuberculosisInfections and infestations | 0/60 | 0/121 | 0/121 | 2/301 |
| PneumoniaInfections and infestations | 0/60 | 0/121 | 0/121 | 2/301 |
| Event | DB Phase - Placebo EOW | DB Phase - Adalimumab 40 mg EOW | DB Phase - Adalimumab 80 mg EOW | Any Adalimumab |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 7/60 | 17/121 | 15/121 | 60/301 |
| NasopharyngitisInfections and infestations | 4/60 | 7/121 | 9/121 | 32/301 |
| Injection site pruritusGeneral disorders | 0/60 | 7/121 | 5/121 | 0/301 |
| Age, Categorical(Participants) | Placebo | Adalimumab 40 mg | Adalimumab 80 mg | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 58 | 115 | 111 | 284 |
| >=65 years | 2 | 6 | 10 | 18 |
| Sex: Female, Male(Participants) | Placebo | Adalimumab 40 mg | Adalimumab 80 mg | Total |
|---|---|---|---|---|
| Female | 49 | 104 | 101 | 254 |
| Male | 11 | 17 | 20 | 48 |
| Region of Enrollment(participants) | Placebo | Adalimumab 40 mg | Adalimumab 80 mg | Total |
|---|---|---|---|---|
| China | 60 | 121 | 121 | 302 |
The record gives a start of Aug 2007, a primary completion of Jul 2008 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab